HFA Icon

GlaxoSmithKline Pleads Guilty illegal Drug Marketing, to Pay $3B Fine

HFA Padded
HFA Staff
Published on
Updated on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

GlaxoSmithKline Pleads Guilty illegal Drug Marketing, to Pay $3B Fine

The biggest player of the pharmaceutical industry, GlaxoSmithKline plc (NYSE:GSK), makes the biggest settlement of healthcare fraud in US trial history. This brings an end to a long-running case against the pharmaceutical giant that was under investigation for many years now. FDA, FBI and Department of Health and Human Services had been probing the matter.

The drugs that the company is paying a huge price for are called Paxil, Wellbutrin and Avandia. While Paxil and Wellbutrin are antidepressants and the criminal charges are 'misbranding', GlaxoSmithKline plc (NYSE:GSK) faced allegations of misrepresenting the...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article
Already a member? Log in here
HFA Padded

The post above is drafted by the collaboration of the Hedge Fund Alpha Team.